How The Oxford Astra-Zeneca Vaccine Works
SKIP TO CONTENT SKIP TO SITE INDEX The Coronavirus Outbreak LIVE Latest Updates Maps and Cases Risk Near You Vaccine Rollout Guidelines After Vaccination U.S.A. World Health How the Oxford-AstraZeneca Vaccine Works By Jonathan Corum and Carl Zimmer Updated March 5, 2021 Leer en español The University of Oxford partnered with the British-Swedish company AstraZeneca to develop and test a coronavirus vaccine known as ChAdOx1 nCoV-19 or AZD1222 . Clinical trials found that the vaccine had an efficacy of 82.4 percent when two doses were given 12 weeks apart. Despite some uncertainty over trial results , Britain authorized the vaccine for emergency use in December, and India authorized a version of the vaccine called Covishield on Jan. 3. A Piece of the Coronavirus The SARS-CoV-2 virus is studded with proteins that it uses to enter human cells. These so-called spike proteins ...
Comments
Post a Comment